Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tal Zaks

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Cancers of the large bowel and hepatobiliary tractTal Zaks, Weijing Sun
Current Topics in Microbiology and Immunology|July 29, 2022
Clinical Development of mRNA Vaccines: Challenges and OpportunitiesAllison August, Luis Brito, Robert Paris, et al.
Nature Reviews. Materials|August 16, 2021
Lipid nanoparticles for mRNA deliveryXucheng Hou, Tal Zaks, Robert Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancerHamouda Boussen, Massimo Cristofanilli, Tal Zaks, et al.
Investigational New Drugs|March 6, 2009
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeuticsMatthew D Galsky, Tal Zaks, Habib Hassani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 7, 2021
mRNA-encoded, constitutively active STING<sup>V155M</sup> is a potent genetic adjuvant of antigen-specific CD8<sup>+</sup> T cell responseSze-Wah Tse, Kristine McKinney, William Walker, et al.
Molecular Cancer Therapeutics|April 17, 2008
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell linesJoel Greshock, Jie Cheng, David Rusnak, et al.
The Lancet. Oncology|April 28, 2009
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II studyBella Kaufman, Maureen Trudeau, Ahmad Awada, et al.
Open Forum Infectious Diseases|July 7, 2022
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy AdultsAllison August, Christine A Shaw, Heather Lee, et al.
Nature Medicine|December 10, 2021
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusAllison August, Husain Z Attarwala, Sunny Himansu, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Cancers of the large bowel and hepatobiliary tractTal Zaks, Weijing Sun
Current Topics in Microbiology and Immunology|July 29, 2022
Clinical Development of mRNA Vaccines: Challenges and OpportunitiesAllison August, Luis Brito, Robert Paris, et al.
Nature Reviews. Materials|August 16, 2021
Lipid nanoparticles for mRNA deliveryXucheng Hou, Tal Zaks, Robert Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancerHamouda Boussen, Massimo Cristofanilli, Tal Zaks, et al.
Investigational New Drugs|March 6, 2009
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeuticsMatthew D Galsky, Tal Zaks, Habib Hassani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 7, 2021
mRNA-encoded, constitutively active STING<sup>V155M</sup> is a potent genetic adjuvant of antigen-specific CD8<sup>+</sup> T cell responseSze-Wah Tse, Kristine McKinney, William Walker, et al.
Molecular Cancer Therapeutics|April 17, 2008
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell linesJoel Greshock, Jie Cheng, David Rusnak, et al.
The Lancet. Oncology|April 28, 2009
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II studyBella Kaufman, Maureen Trudeau, Ahmad Awada, et al.
Open Forum Infectious Diseases|July 7, 2022
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy AdultsAllison August, Christine A Shaw, Heather Lee, et al.
Nature Medicine|December 10, 2021
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusAllison August, Husain Z Attarwala, Sunny Himansu, et al.
Pageof 3